Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
**Cell Chemical Biology**

**Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2**

**Graphical abstract**

**Highlights**
- Development of a sensitive and affordable PLpro activity probe
- Identification of potential SCoV2 PLpro inhibitors through HTS
- Co-crystal structure determination and lead optimization
- Characterization of a submicromolar inhibitor of SCoV2

**Authors**
Hengyue Shan, Jianping Liu, Jiali Shen, ..., Ying Li, Lifeng Pan, Li Tan

**Correspondence**
zhangzheng1975@aliyun.com (Z.Z.), liying@sioc.ac.cn (Y.L.), panlf@sioc.ac.cn (L.P.), tanli@sioc.ac.cn (L.T.)

**In brief**
PLpro represents a putative druggable target for SCoV2. Utilizing multiple approaches, including fluorogenic activity probes, HTS, co-crystallization, structure-based design, and other optimized cellular assays, Shan et al. successfully develop a potent and selective inhibitor of SCoV2 PLpro.

Shan et al., 2021, Cell Chemical Biology 28, 855–865
June 17, 2021 © 2021 Elsevier Ltd.
https://doi.org/10.1016/j.chembiol.2021.04.020
Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2

Hengyue Shan,1,2,6 Jianping Liu,3,6 Jiali Shen,1,2,6 Jialin Dai,1,6 Gang Xu,4,6 Kuankuan Lu,1,2 Chao Han,1,2 Yaru Wang,2,3 Xiaolong Xu,2,3 Yilun Tong,7,4 Huaijiang Xiang,1 Zhiyuan Ai,1 Guanglei Zhuang,5 Junhao Hu,1 Zheng Zhang,4,* Ying Li,1,* Lifeng Pan,2,3,* and Li Tan1,7,*

1Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 201210, China
2University of Chinese Academy of Sciences, Beijing 100049, China
3State Key Laboratory of Bioorganic and Natural Products Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, China
4Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province 518112, China
5State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200240, China
6These authors contributed equally
7Lead contact
*Correspondence: zhangzheng1975@aliyun.com (Z.Z.), liying@sioc.ac.cn (Y.L.), panlf@sioc.ac.cn (L.P.), tanli@sioc.ac.cn (L.T.)
https://doi.org/10.1016/j.chembiol.2021.04.020

SUMMARY

The COVID-19 pandemic has been disastrous to society and effective drugs are urgently needed. The papain-like protease domain (PLpro) of SARS-CoV-2 (SCoV2) is indispensable for viral replication and represents a putative target for pharmacological intervention. In this work, we describe the development of a potent and selective SCoV2 PLpro inhibitor, 19. The inhibitor not only effectively blocks substrate cleavage and immunosuppressive function imparted by PLpro, but also markedly mitigates SCoV2 replication in human cells, with a submicromolar IC50. We further present a convenient and sensitive activity probe, 7, and complementary assays to readily evaluate SCoV2 PLpro inhibitors in vitro or in cells. In addition, we disclose the co-crystal structure of SCoV2 PLpro in complex with a prototype inhibitor, which illuminates their detailed binding mode. Overall, these findings provide promising leads and important tools for drug discovery aiming to target SCoV2 PLpro.

INTRODUCTION

The pandemic of coronavirus disease 2019 (COVID-19) has been ravaging for over a year, causing mounting infections and millions of deaths, as well as incalculable devastation of the global economy (Morens and Fauci, 2020). To overcome COVID-19, researchers worldwide are racing to discover effective drugs. Up to now, several vaccines have been approved, and the US FDA has granted Remdesivir, an antiviral agent targeting RNA polymerase (RdRP), approval for treatment of COVID-19. However, the agents currently applied in the clinic will most likely face anticipated drug resistance arising from the evolving virus (Thomson et al., 2021). Indeed, RdRP inhibitors, e.g., Remdesivir, have already been approved, while Mpro inhibitors have advanced into clinical trials (NCT04535167; NCT04627532). On the other hand, potent and selective inhibitors of SCoV2 PLpro remain to be discovered.

SCoV2 PLpro shares 83% sequence identity as well as proteolytic activity with SCoV PLpro. It can process nonstructural proteins, in particular, nsps 1–3, that are essential for virus replication, and can cleave K48-linked ubiquitin (Ub) chains or interferon-stimulated gene 15 (ISG15) modifications on host cell proteins to counteract the immune response during viral infection (Figure 1A) (Li and De Clercq, 2020). Indeed, RdRP inhibitors, e.g., Remdesivir, have already been approved, while Mpro inhibitors have advanced into clinical trials (NCT04535167; NCT04627532). On the other hand, potent and selective inhibitors of SCoV2 PLpro remain to be discovered.

SCoV2 PLpro shares 83% sequence identity as well as proteolytic activity with SCoV PLpro. It can process nonstructural proteins, in particular, nsps 1–3, that are essential for virus replication, and can cleave K48-linked ubiquitin (Ub) chains or interferon-stimulated gene 15 (ISG15) modifications on host cell proteins to counteract the immune response during viral infection (Figure 1A) (Li and De Clercq, 2020; Ratia et al., 2006; Shin et al., 2020). Previously, selective inhibitors had been developed for SCoV PLpro, which could restrain SCoV replication at high concentrations (Baez-Santos et al., 2014; Ratia et al., 2008). Some of these reported inhibitors were tested against SCoV2 and exhibited only weak to moderate antiviral effects in cells (Freitas et al., 2020; Klemm et al., 2020; Shin et al., 2020).
Of note, given the functional similarity between PLpro and human deubiquitinating enzymes (DUBs), competitive inhibitors of PLpro might potentially hit off-targets in infected cells. Indeed, two peptidomimetic covalent PLpro inhibitors reported recently exhibited in vitro reactivity toward both SCoV2 and a DUB (Rut et al., 2020).

Herein, we present the discovery of a potent and selective SCoV2 PLpro inhibitor, i.e., 19, which efficiently suppressed viral replication with a submicromolar IC₅₀. In addition, several optimized approaches are described to facilitate the identification and optimization of SCoV2 PLpro inhibitors, including drug design based on the co-crystal structure of SCoV2 PLpro in Figure 1.
complex with an inhibitor; development of enzymatic activity assays that allow quick, large-scale, and affordable high-throughput screening (HTS); and implementation of a virus-free experimental system ready to assess cellular potency of lead compounds.

RESULTS

Development of peptidomimetic activity probes for SCoV2 PLpro

As PLpro and DUBs share conserved target cleavage sites, we screened several reported DUB substrates to develop an enzymatic activity assay for SCoV2 PLpro (Figures 1B, 1C, and S1).

The purified recombinant SCoV2 PLpro protein exhibited robust activity in cleaving K48-linked diUb, but weak or no activity against K63-linked or linear diUb, respectively (Figure S1). SCoV2 PLpro could readily cleave a Ub-rhodamine 110 conjugate (Ub-Rho/1) (Hassepein et al., 2007) and release the fluorophore (Rho) from its C terminus. We demonstrated that it could likewise release the fluorogenic 7-amido-4-methylcoumarin (AMC) from the peptidomimetic probes 2 and 3, which harbored a conserved RLGG sequence homologous to the C-terminal pentapeptide of Ub (Figures 1B and 1D) (Renatus et al., 2006).

To better mimic the isopeptide bond of SCoV2 PLpro substrates, we synthesized a hexapeptide probe (5) with a fluorogenic 7-hydroxy-3-carboxycoumarin (HCC) conjugated to its N terminus, and a 4-(dimethylaminoazo) benzene-4-carboxylic acid (DABCYL) to its C-terminal lysine (Figures 1B and S2). The maximal absorption of the HCC fluorophore in 5 is around 410 nm, and its emission peak is at 450 nm. In the absence of SCoV2 PLpro, the emission of HCC upon excitation will mostly be quenched by the proximate DABCYL subunit in 5 through a fluorescence resonance energy transfer (FRET) mechanism. In the presence of SCoV2 PLpro, 5 will be cleaved and the resultant fluorogenic pentapeptide (5') will no longer be quenched (Figures 1C and S2). Compared with previous probes, 5 exhibited improved sensitivity to SCoV2 PLpro with lower background signal. We then replaced the N-terminal lysine of 5 with a methionine to mimic the linear diUb (6), or with an aliphatic chain (7), and observed that 6 was slightly less sensitive, whereas 7 was as sensitive as 5 (Figures 1B–1D).

To optimize the SCoV2 PLpro enzymatic activity assays with 5 and 7, we titrated each probe and confirmed that 6 or 7 at 2.5 μM was efficient enough (Figure 1E). Then we set probes at 2.5 μM and titrated SCoV2 PLpro, and confirmed 1 μM as an efficient concentration for the enzyme. Under the optimized conditions, both 5 and 7 exhibited excellent sensitivity to wild-type (WT) SCoV2 PLpro, but not to the catalytically inactive mutant, SCoV2 PLproC112S (Figure 1F). However, the K_m value for 7 is 3-fold lower than that for 5 (Figure 1G), suggesting that 7 represents a better substrate for SCoV2 PLpro.

Screening for SCoV2 PLpro inhibitors

Having established the enzymatic activity assay with 7, we initially screened 25 reported inhibitors of DUB or DUB-like proteases for their inhibitory activity against SCoV2 PLpro at 10 μM (Figures 2A and 2B and Table S1). Most molecules were weak (< 30% inhibition) or inactive against SCoV2 PLpro, except for a UCHL3 inhibitor, TCID (Liu et al., 2003), which showed moderate inhibition (~50%). Among these compounds, the SCoV PLpro inhibitor GRL0617 (Ratia et al., 2008), recently reported to inhibit SCoV2 PLpro in vitro (Freitas et al., 2020; Shin et al., 2020), stood out, with over 80% inhibition of SCoV2 PLpro in our assays, as expected.

Using GRL0617 as a positive control, the SCoV2 PLpro enzymatic activity assay was further optimized to suit HTS, with a Z'-factor of 0.633 determined by 100 wells per control group (Zhang et al., 1999). Then we performed a primary screen on 35,360 diverse compounds, including lead-like fragments, FDA-approved drugs, and small molecules with reported biological activities. This HTS was repeated and resulted in a moderate hit rate of 0.037% with the Z'-score threshold set at ~8, representing a strong negative effect (Zhang, 2007). A total of 13 compounds were selected for further validation (Figures 2C and 2D and Table S1).

Of the 13 hits, 9 reproducibly inhibited SCoV2 PLpro, with at least 25% inhibitory activity, and 7 exhibited over 50% inhibition, including an essential nutrient, vitamin B12, and inhibitors reported for other targets, such as avasimibe and tiplaxtinin. An antibiotic commonly used in hair shampoo, zinc pyrithione, and an electrophilic α-chloroketone, compound 8, showed potency comparable to that of GRL0617. Given its high hydrolytic activity but low selectivity toward Ub chain linkages (Ritorto et al., 2014), the deubiquitinating protease USP2 was used in a counter-screen to study the selectivity of all these hits, and the results indicated GRL0617 to be more selective than others (Figure 2D). GRL0617, which had already been optimized for SCoV PLpro, generally showed superior potency, selectivity, and molecular complexity than other hits. These findings are consistent with previously reported HTS results (Smith et al., 2020) and support that GRL0617 serves as a better lead for SCoV2 PLpro.

Determination of the co-crystal structure of the SCoV2 PLpro-12 complex

Encouraged by the potential of GRL0617, we synthesized and tested a series of reported SCoV PLpro inhibitors (11–13) that partially resemble GRL0617 with a shared naphthyl subunit (Baez-Santos et al., 2014). These inhibitors exhibited even better potency than GRL0617 in our assay based on 7, with IC_{50} values ranging between 2.6 and 4.3 μM (Figures 3A and S3). To study the pharmacophore of this series of inhibitors and to facilitate the following chemical optimization, we attempted to co-crystallize SCoV2 PLpro with these inhibitors (11–13). We first determined the high-resolution apo-form structure of the catalytically inactive mutant, SCoV2 PLproC112S (Figure S4A). More importantly, the co-crystal structure of the SCoV2 PLproC112S-12 complex was solved at 2.4 Å resolution as a dimer. Although the overall R_{free} (0.326) and R_{model} (0.272) values for the co-crystal are relatively high due to the anisotropy of diffraction data, particularly in the resolution range of 3.15–2.4 Å, the electron-density map of the binding site shows good quality, and 12 can be well traced in the map (Figures 3B and 3C and Table S2). Based on the co-crystal structure, 12 adopts a U-shape conformation to occupy a pocket between the S1 site and the catalytic site of SCoV2 PLpro, consequently blocking the N-terminal moiety of its substrates from accessing the S1 site (Figure 3B). Notably, the 2mFo-DFc electron-density maps indicated distinct binding modes for each unit of the asymmetrically
dimerized complex (Figure 3C). Nevertheless, further analyses were based on the complex structure of chain A only, given its better quality of electron density compared with chain B. Upon closer examination, 12 interacts with the side chains of multiple surrounding residues, including Leu163, Pro248, Pro249, Tyr265, Tyr269, and Gln270, through van der Waals forces. In particular, the phenyl ring of Tyr269 simultaneously engages with all three hydrophobic rings of 12, acting as a latch of the binding pocket. In addition, the carbonyl of Tyr269 forms an H bond with the backbone amide of 12. Moreover, the electrostatic interaction between the negatively charged Asp165 and the positively charged tertiary amine of 12 further stabilizes the complex (Figures 3C and 3D).

Upon binding to SCoV2 PLpro, 12 pushes the side chain of Leu163 away from its binding pocket, but induces the side chain of Tyr269 to bend down steeply toward it (Figures 3D and S4A). Likewise, GRL0617 induces similar conformational changes in Leu163 and Tyr269, but to a lesser extent (PDB: 7JFR) (Osipiuk et al., 2021). In contrast, GRL0617 forms an H bond with the backbone nitrogen of Gln270, and induces significant conformational change in it (Figure 3D). Binding with Ub or ISG15 also induces the side chain of Tyr269 to bend down; however, it bends toward Pro248 rather than the binding pocket (Figure S4B) (Klemm et al., 2020; Shin et al., 2020). Collectively, 12 efficiently exploits the switchable Tyr269 to inhibit SCoV2 PLpro.

**Optimization of SCoV2 PLpro inhibitors**

Based on the co-crystal structure, we performed structure-activity relationship (SAR) studies to optimize the SCoV2 PLpro inhibitors. Given that derivatization of the naphthyl group is reportedly unfavorable (Baez-Santos et al., 2014), and as the piperidyl ring is tightly surrounded by Tyr269, Asp165, and other residues, we focused our efforts on the substitution of benzyl group (Figures 3 and S3). First, inspired by 11, we added a 5-fluorine to 12 to strengthen the interaction with Gln270, and the resultant 14 showed improved potency. Meanwhile, as the substituted benzyl group of 12 is exposed to the solution, we postulated that hydrophilic substituents might stabilize the complex. However, replacing the hydrophobic benzyl ring of 12 with a substituted piperidine ring (15) resulted in potency decrease. To introduce hydrophilic substitutions without disturbing the hydrophobic interaction between 12 and Gln270 and Leu163, we decided to modify the acetamide group, which seems to protrude toward the solvent in the co-crystal, rather than the whole benzyl ring. As expected, both 16 and 17, each introduced with a hydrophilic tertiary amine, showed improved potency compared...
with 12 and 15, while 17 showed a submicromolar IC50. Finally, we added 5-fluorine to 16 and 17 to generate 18 and 19 with further improved potency. All these analogs were also tested in a SCoV2 PLpro activity assay based on Ub-Rho, and their relative activities were overall consistent with those based on 7 (Figures 3 A and S3).

Given the unsuccessful efforts to co-crystalize SCoV2 PLpro with 19 or other analogs, we performed molecular docking studies to elucidate the outstanding potency of 19 based on the co-crystal structure of SCoV2 PLpro-12 (Figures 4A–4C). The docking results predicted a binding mode for 19, which is partially similar to that of 12, but includes additional interactions for 19. Based on this mode, the substituted piperazine group and the 5-fluorine of 19 interact with the side chains of Tyr269 and Gln270, respectively, mainly through van der Waals forces. Compared with 12, which interacts with Tyr269 in three...
orthogonal directions, 19 almost encircles Tyr269 with interactions in four orthogonal directions, which provides a plausible explanation for its significantly improved potency (Figure 4C).

To precisely characterize the affinity of 19 for SCoV2 PLpro, we performed surface plasma resonance (SPR) binding analysis of 19 in comparison with GRL0617. Based on the SPR results, 19 bound to SCoV2 PLpro with a $K_d$ of 2.6 μM, while that of GRL0617 was 10.8 μM (Figure 4D). To evaluate its selectivity, 19 was profiled against 10 DUBs or DUB-like proteases, including USP14 and OTUB1, which reportedly favor K48-linked Ub chains as substrates. Compared with SCoV2 PLpro, none of these 10 proteases were significantly inhibited by 19 at 10 μM (Figure 4E). Cumulatively, the results show that 19 is a potent and selective inhibitor of SCoV2 PLpro in vitro.

**Inhibitor 19 and analogs effectively inhibited SCoV2 PLpro in live cells**

To investigate if 19 and other analogs maintain their potency in live cells, we designed a cellular assay to assess the enzymatic activity of SCoV2 PLpro (Figure 5A). We found that SCoV2 nsp1-nsp2 protein expressed in 293T cells is rather stable despite endogenous human DUBs, but can be readily
Figure 5. Inhibitor 19 and analogs inhibited SCoV2 PLpro and viral replication in live cells.

(A) Inhibitors 17, 18, and 19 inhibited the cleavage of recombinant nsp1-nsp2 by SCoV2 PLpro in a dose-dependent manner. 293T cells were pretreated with each inhibitor at the indicated concentrations and transfected with FLAG-tagged nsp1-nsp2 and SCoV2 PLpro for 24 h, followed by western blots.

(B) Inhibitors 17, 18, and 19 significantly recovered the activation level of NF-κB perturbed by SCoV2 PLpro. NF-κB-luc-reporting 293T cells were transfected with SCoV2 PLpro WT or PLpro C112S for 18 h in the presence of inhibitors (10 μM) and then stimulated by TNF-α for 6 h and measured for their NF-κB activity by the luciferase reporting system. Data are presented as the mean ± SD (n = 3, ***p < 0.001).

(C) Inhibitors 17, 18, and 19 significantly recovered the level of ISGylation perturbed by SCoV2 PLpro. A549 cells stably expressing SCoV2 PLpro WT or PLpro C112S were preincubated with inhibitors for 6 h and then stimulated by IFN-α for 24 h and subjected to western blots.

(D) Inhibitors 15–17 at 5 μM abolished SCoV2 replication in hACE2-HeLa cells. hACE2-HeLa cells were infected with SCoV2 (0.3 MOI) for 1 h, then washed out with PBS, and cultured with normal medium and the indicated inhibitors (5 μM) for an additional 48 h, followed by western blots.

(E) Inhibitor 19 inhibited the replication of SCoV2 in human cells in a dose-dependent manner. hACE2-HeLa cells were infected with SCoV2 for 1 h, then washed out with PBS, and cultured with normal medium and the indicated inhibitors (5 μM) for another 48 h, followed by immunostaining of spike protein (red) and nuclei (blue). Assays were repeated at least three times with similar results, and representative images are shown.

(F) Inhibition of SCoV2 replication curves based on the quantification of fluorescence, and the calculated IC50, CC50, and therapeutic indexes (CC50/IC50) for 17–19. Data are presented as the mean ± SD (n = 3).
cleaved into two parts by the co-expressed SCoV2 PLpro protein. However, such cleavage should be perturbed by SCoV2 PLpro inhibitors. And to our satisfaction, 17, 18, and 19 at 10 μM all significantly inhibited SCoV2 PLpro in 293T cells.

As PLpro putatively impairs the immune response of host cells, to further evaluate our inhibitors for their cellular efficacy, we checked their modulatory effects on the immune signaling regulated by K48-linked Ub chains or ISGylation in live cells. Based on a luciferase-reporting assay, we confirmed that expression of SCoV2 PLpro\textsuperscript{WT} notably decreased NF-κB activation in 293T cells. In contrast, expression of catalytically inactive PLpro\textsuperscript{K125S} led to a much weaker effect, and 17, 18, or 19 at 10 μM could significantly recover the activation level of NF-κB (Figure 5B). We also confirmed that expression of SCoV2 PLpro significantly decreased the overall ISGylation induced by interferon-α (IFN-α) in A549 cells, which could be efficiently restored by all three inhibitors (Figure 5C). These results further corroborated that 19 and analogs are effective SCoV2 PLpro inhibitors in human cells.

**Inhibitor 19 and analogs effectively mitigate the replication of SCoV2 in cells**

As GRL0617 and other reported inhibitors exhibited sufficient antiviral effects only at rather high concentrations, we sought to test our inhibitors in HACE2-HeLa cells (Zhou et al., 2020) for their antiviral potency. As the nucleocapsid protein (NP) is a reliable biomarker for indicating the replication rate of SCoV2 in cells, we checked the NP level in infected hACE2-HeLa cells treated with each inhibitor. Based on western blot analysis, the reported inhibitors at 5 μM only moderately or weakly decreased the NP level, with 11 as the strongest. In contrast, our optimized analogs exhibited obviously improved potency, and 15, 16, or 17 almost completely diminished the expression of NP in infected cells (Figure 5D).

Immunostaining of the spike protein demonstrated that SCoV2 viruses replicated effectively in HACE2-HeLa cells, which consequently induced severe cell death (Figure 5E). Consistently, inhibitors 15–19 alleviated both replication of SCoV2 and the death of hACE2-HeLa cells in a dose-dependent manner, while 19 could significantly inhibit SCoV2 replication even at 400 nM (Figures 5E and S5B). On the other hand, at 10 μM, neither 17 nor 19 showed detectable cytotoxicity in HACE2-HeLa cells, whereas 18 did reduce the cell viability to nearly 60% compared with the control (Figure S5A). Based on the quantification of immuno-fluorescence, the IC\textsubscript{50} values for 17–19 all fell within the nanomolar range, yet 19 remained the best, with a IC\textsubscript{50} of 182 nM and a therapeutic index (CC\textsubscript{50}/IC\textsubscript{50}) over 55 (Figure 5F). Together, these results show that 19 can effectively and selectively inhibit the replication of SCoV2 in human cells.

**DISCUSSION**

HTS could be an efficient approach to providing promising pharmacophores for the development of SCoV2 PLpro inhibitors. However, its success rate depends not only on the capacity and diversity of screened chemical libraries, but also on the robustness, convenience, and cost efficiency of the HTS assays. Among the reported fluorogenic activity probes for DUBs and SCoV PLpro, Ub-Rho is very sensitive, but too expensive for HTS. AMC-based peptidomimetic probes like 2 or 3 are moderately sensitive and much more cost effective. However, they often interfere with the screened fluorescent compounds with overlapping spectrums. In contrast, our FRET-based fluorogenic probe 7 exhibited excellent sensitivity with minimal background for SCoV2 PLpro and showed high reliability and low cost in HTS.

With probe 7 we screened reported inhibitors of DUBs or other proteases, performed a pilot HTS, and successfully identified several hits for SCoV2 PLpro. Some of these hits demonstrated encouraging chemical properties for further development. For example, avasimibe and tiplaxtinin could be repurposed and optimized for SCoV2 PLpro, whereas zinc pyrithione and 8 might potentially serve as covalent fragments in the design of covalent inhibitors of SCoV2 PLpro. Of particular importance, a series of SCoV PLpro inhibitors, including GRL0617 and 11–13, were identified as the best leads for SCoV2 PLpro in the current study. Thus, we determined the co-crystal structure of the 12-SCoV2 PLpro complex, which complemented well the recently reported structures of SCoV2 PLpro complexes (Fu et al., 2021; Gao et al., 2021; Osipiuk et al., 2021) and greatly facilitated our SAR studies. An optimized analog, 19, proved to be a potent and selective inhibitor of SCoV2 PLpro in vitro.

We have utilized several cellular assays in combination to evaluate our inhibitors in live cells. These assays are based on the cleavage of nsp proteins or ISGylation by SCoV2 PLpro, or based on its viral suppression of the host immune response. Indeed, 19 and other analogs exhibited robust inhibition of SCoV2 PLpro in these assays. Furthermore, we demonstrate that 19 is a remarkably more effective antiviral agent, compared with the reported analogs, and can mitigate the replication of SCoV2 in human cells with submicromolar IC\textsubscript{50} values. Based on the preliminary evaluation, 19 exhibited moderate metabolic stability in mouse liver microsomes or plasma with half-lives of 28.0 or over 120 min, respectively (Figure S5C), and is warranted to be further assessed with animal models in the future.

In summary, we report the development of 19 as a potent and selective inhibitor of SCoV2 PLpro and demonstrate a repertoire of complementary approaches to facilitate drug discovery for SCoV2. Our sensitive and affordable activity probe, 7, could considerably expand the capacity of HTS and accelerate the identification of new hits; the virus-free cellular assays utilized in this work are feasible and can be very helpful in the early stage of development with limited resources, such as P3 laboratories; the detailed binding mode of 12-SCoV2 PLpro, revealed by a co-crystal structure, will certainly assist inhibitor design and optimization; and last, 19 has provided an optimized pharmacophore and a promising lead for further developments. Collectively, these findings represent a small but solid milestone in the arduous and prolonged battle against COVID-19.

**Limitations of the study**

Despite the favorable potency and selectivity of 19 in cultured cells, further evaluation of the efficacy and tolerability of 19 in vivo is necessary to establish its translational relevance to COVID-19. On the other hand, probe 7 may be incapable of screening for inhibitors that target other allosteric sites of SCoV2 PLpro. Thus, it should be considered as a complement to, rather than a
substitute for, Ub-based probes. In addition, our efforts to cocrystallize SCoV2 PLpro bound to 19 were unsuccessful, and other advanced technologies, e.g., cryogenic electron microscopy, could help solve this obstacle and facilitate further optimization of 19.

SIGNIFICANCE
COVID-19 has struck our society as a great calamity, and the need for effective drugs is more urgent than ever. PLpro is one of the most promising druggable targets of SCoV2; however, current small-molecule inhibitors of SCoV2 PLpro exhibit only weak to moderate inhibition of SCoV2 replication and the death of infected cells, with a submicromolar IC₅₀. This study reports the development of potent and selective inhibitors of SCoV2 PLpro that effectively inhibit replication of SCoV2 and the death of infected cells, with a submicromolar IC₅₀. We also describe a repertoire of complementary approaches to aid in drug development, including a fluorogenic probe with better sensitivity than reported peptidomimetic probes, which is more affordable than Ub-based probes and compatible with high-throughput screening to identify SCoV2 PLpro inhibitors. Several virus-free cellular assays are optimized to assess the enzymatic activity of SCoV2 PLpro, which can be very useful to evaluate the potency of candidate inhibitors in live cells outside of P3 labs. Structural studies reveal the detailed binding mode of the pharmacophore to be optimized, and our lead compounds effectively inhibit replication of SCoV2 and the death of infected cells with submicromolar IC₅₀.

STAR METHODS
Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Materialia availability
  - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Cell lines and cell culture
- METHOD DETAILS
  - Protein expression and purification
  - Preparation of Di-Ubiquitin proteins
  - Protein crystallization and structural determination
  - Molecular docking study
  - Absorption and emission spectra
  - Kinetic assays
  - Kₑₑ value determination
  - HTS screening
  - IC₅₀ value determination
  - SPR analysis
  - Inhibitor specificity assay
  - Nsp1-Nsp2 cleavage assay
  - NF-κB activity luciferase-reporting assay
  - DeSGylation assay
  - SARS-CoV2 infection and evaluation of antiviral activities
  - Metabolic stability studies
  - Chemical synthesis
- QUANTIFICATION AND STATISTICAL ANALYSIS

SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.chembiol.2021.04.020.

ACKNOWLEDGMENTS
We thank Dr. Sara J. Buhrlage (Harvard) for her generous help with the reported DUB and DUB-like protease inhibitors, Dr. Sheng-Ge Tao (Shanghai Jiao Tong University) for the cDNA of SCoV2 PLpro, Dr. Zaorong Zhang (IRCBC, CAS) for DUB plasmids, Dr. Deju Ye (Nanjing University) for help with development of fluorogenic probes, and Dr. Zhaoxin Wang (IRCBC, CAS) for help with the metabolic stability studies. This work was supported by grants from the National Natural Science Foundation of China (21778066 to L.T., 31801163 to Y.L., 21822705 to J.L. and L.P., 32071297 to J.L., and 21621002 to L.P.), Shanghai Municipal Science and Technology Commission (18ZR1448400 to Y.L., 20XD1425200 to L.P., 18JC1420500 and Major Project 2019SHZDX02 to L.T.), and the Strategic Priority Research Program of the Chinese Academy of Sciences (XDB39030500 to L.T. and XDB20000000 to L.P.).

AUTHOR CONTRIBUTIONS
Conceptualization, L.T., L.P., and Y.L.; methodology, S.H., J.L., J.S., G.X., and Y.L.; software, L.P. and Y.L.; formal analysis, H.S., J.L., J.S., Y.T., H.X., Y.L., and L.T.; investigation, H.S., J.L., J.S., J.D., G.X., K.L., C.H., Y.W., X.X., Y.T., and Z.A.; resources, L.P. and Z.Z.; writing – original draft, L.T., Y.L., and G.Z.; supervision, L.T., L.P., Y.L., Z.Z., and J.H.; funding acquisition, L.T., L.P., and Y.L.

DECLARATION OF INTERESTS
The authors declare no competing interest.

Received: November 29, 2020
Revised: March 2, 2021
Accepted: April 23, 2021
Published: May 12, 2021

REFERENCES
Abulwerdi, F., Liao, C., Liu, M., Azmi, A.S., Aboukameel, A., Mady, A.S., Gulappa, T., Cierpicki, T., Owens, S., Zhang, T., et al. (2014). A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo. Mol. Cancer Ther. 13, 565–575.
Akwabi-Ameyaw, A., Baas, J.Y., Caldwell, R.D., Caravella, J.A., Chen, L., Creech, K.L., Deaton, D.N., Jones, S.A., Kaldor, I., Liu, Y., Madauss, K.P., et al. (2008). Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064. Bioorg. Med. Chem. Lett. 18, 4339–4343.
Attun, M., Kramer, H.B., Willems, L.J., McDermott, J.L., Leach, C.A., Goldenberg, S.J., Kumar, K.G., Konietzny, R., Fischer, R., Kogan, E., et al. (2011). Activity-based chemical proteomics accelerates inhibitor development for debiquitylating enzymes. Chem. Biol. 18, 1401–1412.
Baez-Santos, Y.M., Barraza, S.J., Wilson, M.W., Agius, M.P., Mielech, A.M., Davis, N.M., Baker, S.C., Larsen, S.D., and Mesecar, A.D. (2014). X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases. J. Med. Chem. 57, 2393–2412.
Banerjee, R., and Ragadale, S.W. (2003). The many faces of vitamin B12: catalysis by cobalamin-dependent enzymes. Annu. Rev. Biochem. 72, 209–247.
Bartholomeusz, G.A., Talpaz, M., Kapuria, V., Kong, L.Y., Wang, S., Estrov, Z., Priebe, W., Wu, J., and Donato, N.J. (2007). Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood 109, 3470–3478.

Cencic, R., Hall, D.R., Robert, F., Du, Y., Min, J., Li, L., Qui, M., Lewis, I., Kurtkaya, S., Dingledine, R., et al. (2011). Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. Proc. Natl. Acad. Sci. U S A 108, 1046–1051.

Colombo, M., Valiese, S., Peretto, I., Jacq, X., Rain, J.C., Colland, F., and Guedat, P. (2010). Synthesis and biological evaluation of 9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile analogues as potential inhibitors of deubiquitinating enzymes. ChemMedChem 5, 522–528.

Ding, Q., Zhang, Z., Liu, J.J., Jiang, N., Zhang, J., Ross, T.M., Chu, X.J., Bartkovicz, D., Podlaski, F., Janson, C., et al. (2013). Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J. Med. Chem. 56, 5979–5983.

Emsley, P., Lohkamp, B., Scott, W.G., and Cowtan, K. (2010). Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501.

Ermolyayeva, E., and Sanders, D. (1995). Mechanism of pyrithione-induced membrane depolarization in Neurospora crassa. Appl. Environ. Microbiol. 61, 3385–3390.

Finney, J.P., Wood-Baker, R., Thomson, H., and Holgate, S.T. (1992). Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am. Rev. Respir. Dis. 145, 746–749.

Freitas, B.T., Durie, I.A., Murray, J., Longo, J.E., Miller, H.C., Crich, D., Hogan, R.J., Tripp, R.A., and Pegan, S.D. (2020). Characterization and noncovalent inhibition of the deubiquitinase and delISGylase activity of SARS-Cov-2 papain-like protease. ACS Infect Dis. 6, 2099–2109.

Friesner, R.A., Murphy, R.B., Repasky, M.P., Frye, L.L., Greenwood, J.R., Halgren, T.A., Sanschagrin, P.C., and Mainz, D.T. (2006). Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 49, 2099–2109.

Fu, Z., Huang, B., Tang, J., Lashuel, H., Cui, W., Xiong, Y., Zhu, W., Liu, Z., Liu, S., Liu, M., Ye, Y., Liu, S., Xiong, Y., Zhu, W., Cao, D., et al. (2021). The complex structure of GRL0617 and SARS-Cov-2 PLpro reveals a hot spot for antiviral drug discovery. Nat. Commun. 12, 488.

Gao, X., Qin, B., Chen, P., Zhu, K., Hou, P., Woydyla, J.A., Wang, M., and Cui, Y. (2021). Crystal structure of SARS-Cov-2 papain-like protease. Acta Pharm. Sin. B 11, 237–245.

Gauthier, J.Y., Chauret, N., Cromlish, W., Desmarais, S., Duong, L.T., Tomonaga, M., Yamamoto, N., and Fujii, M. (2002). Bay 11-7082 inhibits transcriptional activation of NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood 100, 1829–1834.

Nicholson, B., Leach, C.A., Goldberg, S.J., Francis, D.M., Kodrasov, M.P., Tian, X., Shanks, J., Stener, D.E., Bernal, A., Mattner, M.R., et al. (2008). Characterization of ubiquitin and ubiquitin-like-protein isopeptidase activities. Protein Sci. 17, 1035–1043.

Ospiuk, J., Azi, S.A., Dvorkin, S., Endres, M., Jedrzejczak, R., Jones, K.A., Kang, S., Kathayat, R.S., Kim, Y., Lisnyak, V.G., et al. (2021). Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors. Nat. Commun. 12, 743.

Piotrowski, J., Beal, R., Hoffman, L., Wilkinson, K.D., Cohen, R.E., and Pickart, C.M. (1997). Inhibition of the 26 S proteasome by polyubiquitin chains synthesized to have defined lengths. J. Biol. Chem. 272, 23712–23721.

Ratia, K., Pegan, S., Takayama, J., Sleeman, K., Coughlin, M., Balti, S., Chaudhuri, R., Fu, W., Prabhakar, B.S., Johnson, M.E., et al. (2008). A noncovalent class of papain-like protease/deubiquitinating enzyme inhibitors blocks SARS virus replication. Proc. Natl. Acad. Sci. U S A 105, 16119–16124.

Ratia, K., Saikatendu, K.S., Santarisci, B.D., Barretto, N., Baker, S.C., Stevens, R.C., and Mesecar, A.D. (2006). Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme. Proc. Natl. Acad. Sci. U S A 103, 5717–5722.

Renatus, M., Parrado, S.G., D’Arcy, A., Eidhoff, U., Gerhartz, B., Hassiepen, U., Pierrat, B., Riedl, R., Vinzenz, D., Worpenburg, S., et al. (2006). Structural basis of ubiquitin recognition by the deubiquitinating protease USP22. Structure 14, 1293–1302.

Ritorto, M.S., Ewan, R., Perez-Oliva, A.B., Knebel, A., Buhrlage, S.J., Wightman, M., Kelly, S.M., Wood, N.T., Virdee, S., Gray, N.S., et al. (2014). Screening of DUB activity and specificity by MALDI-TOF mass spectrometry. Nat. Commun. 5, 4763.

Rut, W., Lv, Z., Zmudzinski, M., Patchett, S., Nayak, D., Snipes, S.J., El Ouailid, F., Huang, T.T., Bekes, M., Drag, M., et al. (2020). Activity profiling and crystal structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. D Struct. Biol. 75, 861–877.

Liang, Q., Dixneuf, T.S., Zhang, P., Rosenthal, A.S., Villamil, M.A., You, C., Zhang, Q., Chen, J., Ott, C.A., Sun, H., et al. (2014). A selective USP1-UAF1 inhibitor links deubiquitination to DNA damage responses. Nat. Chem. Biol. 10, 298–304.

Liu, Y., Lashuel, H., Choi, S., Xing, X., Case, A., Ni, J., Yeh, L.A., Cuny, G.D., Stein, R.L., and Lansbury, P.T., Jr. (2003). Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem. Biol. 10, 837–846.

Mori, N., Yamada, Y., Ikeda, S., Yamasaki, Y., Tawkasaki, K., Tanaka, Y., Tomonaga, M., Yamamoto, N., and Fuji, M. (2002). Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood 100, 1829–1834.

Lee, B.H., Lee, M.J., Park, S., Oh, D.C., Elsasser, S., Chen, P.C., Gartner, C., Dimova, N., Hanna, J., Gygi, S.P., et al. (2010). Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 467, 179–184.

Li, G., and De Clercq, E. (2020). Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat. Rev. Drug Discov. 19, 149–150.

Dimova, N., Hanna, J., Gygi, S.P., et al. (2010). Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. D Struct. Biol. 75, 861–877.

Doi, T., and Seidler, U.E. (2017). IL-1beta inhibitors: new hope to COVID-19. Cell 183, 837.
structures of inhibitor-bound SARS-CoV-2 papain-like protease: a framework for anti-COVID-19 drug design. Sci. Adv. 6, eabd4596.

Shao, S., Li, S., Qin, Y., Wang, X., Yang, Y., Bai, H., Zhou, L., Zhao, C., and Wang, C. (2014). Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia. Int. J. Oncol. 44, 1661–1668.

Shin, D., Mukherjee, R., Grewe, D., Bojkova, D., Baek, K., Bhattacharya, A., Schulz, L., Widera, M., Mehdipour, A.R., Tascher, G., et al. (2020). Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature 587, 657–662.

Smith, E., Davis-Gardner, M.E., Garcia-Ordonez, R.D., Nguyen, T.T., Hull, M., Chen, E., Baillargeon, P., Scampavia, L., Strutzenberg, T., Griffin, P.R., et al. (2020). High-throughput screening for drugs that inhibit papain-like protease in SARS-CoV-2. SLAS Discov. 25, 1152–1161.

Takeuchi, N., Nakamura, T., Takeuchi, F., Hashimoto, E., and Yamamura, H. (1992). Inhibitory effect of mitoxantrone on activity of protein kinase C and growth of HL60 cells. J. Biochem. J. Biochem. 112, 762–767.

Weinstock, J., Wu, J., Cao, P., Kingsbury, W.D., McDermott, J.L., Kodrasov, M.P., McKelvey, D.M., Suresh Kumar, K.G., Goldenberg, S.J., Mattern, M.R., and Nicholson, B. (2012). Selective dual inhibitors of the cancer-related deubiquitylating proteases USP7 and USP47. ACS Med. Chem. Lett. 3, 789–792.

Williams, C.J., Headd, J.J., Moriarty, N.W., Prisant, M.G., Videau, L.L., Deis, L.N., Verma, V., Keedy, D.A., Hintze, B.J., Chen, V.B., et al. (2018). MoProBity: more and better reference data for improved all-atom structure validation. Protein Sci. 27, 293–315.

Yang, Y., Kitagaki, J., Dai, R.M., Tsai, Y.C., Lorick, K.L., Ludwig, R.L., Pierre, S.A., Jensen, J.P., Dvadalov, I.V., Oberoi, P., et al. (2007). Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res. 67, 9472–9481.

Zang, R., Gomez Castro, M.F., McCune, B.T., Zeng, Q., Rothlauf, P.W., Sonnek, N.M., Liu, Z., Bruijs, K.F., Wang, X., Greenberg, H.B., et al. (2020). TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci. Immunol. 5, eabc3582.

Zhang, J.H., Chung, T.D., and Oldenburg, K.R. (1999). A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4, 67–73.

Zhang, X.D. (2007). A new method with flexible and balanced control of false negatives and false positives for hit selection in RNA interference high-throughput screening assays. J. Biomol. Screen. 12, 645–655.

Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., Shi, H.R., Zhu, Y., Li, B., Huang, C.L., et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273.
### STAR METHODS

**KEY RESOURCES TABLE**

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| Monoclonal ANTI-FLAG® M2-Peroxidase (HRP) antibody produced in mouse | Sigma-Aldrich | Cat# A8592; RRID: AB_439702 |
| β-Tubulin Mouse MAb | Transgen | Cat# HC101 |
| ISG15 Recombinant Rabbit MAb | Invitrogen | Cat# 703131; RRID: AB_2784562 |
| SARS-CoV / SARS-CoV-2 Spike Rabbit PAb | SinoBiological | Cat# 40150-T62 |
| β-Actin Mouse MAb | Transgen | Cat# HC201 |
| SARS-CoV-2 nucleocapsid protein Rabbit MAb | SinoBiological | Cat# 40143-R019 |
| **Bacterial and virus strains** |        |            |
| E.coli BL21 (DE3) | Lifeng Pan’s laboratory, Shanghai Institute of Organic Chemistry | BL21 (DE3) |
| SARS-CoV2 (SZ02) | Shenzhen Third People’s Hospital | SZ02 |
| **Chemicals, peptides, and recombinant proteins** |        |            |
| Recombinant Human Ubiquitin | BostonBiochem | Cat# U-555 |
| Rhodamine 110 Protein, CF | Li Tan’s laboratory | N/A |
| Probe 2-7 | This paper | N/A |
| SARS-CoV2-PLpro<sup>WT</sup> | This paper | N/A |
| SARS-CoV2-PLpro<sup>C112S</sup> | This paper | N/A |
| Recombinant Human FLAG-USP36 Protein, CF | BostonBiochem | Cat# E-628-025 |
| Recombinant Human His6 USP14 | Li Tan’s laboratory | N/A |
| Recombination Human His6 USP8 | BostonBiochem | Cat# E-520 |
| Recombination Human His6 USP7 | BostonBiochem | Cat# E-519 |
| Recombinant Human His6 USP2 | Li Tan’s laboratory | N/A |
| Recombination Human UCH-L1/PGP9.5 | BostonBiochem | Cat# E-340 |
| Recombination Human His6 SUMO-Specific Peptidase 1/SENP1 Catalytic Domain | BostonBiochem | Cat# E-700 |
| Recombinant Human His6 OTUB1 | Li Tan’s laboratory | N/A |
| Recombination Human Ataxin-3 Like | BostonBiochem | Cat# E-343 |
| Recombination Human AMSH/STAMBP protein | Novus Biologicals | Cat# NBP2-22825 |
| Recombinant Human TNFα | NovoProtein | Cat# C008 |
| Recombinant human Interferon alpha | Sigma-Aldrich | Cat# SRP4595 |
| K48-linked diUb | This paper | N/A |
| K63-linked diUb | This paper | N/A |
| M1-linked diUb | This paper | N/A |
| Aloxistatin | Selleck (Zang et al., 2020) | CAS 88321-09-9 |
| b-AP15 | Selleck (Ward et al., 2020) | CAS 1009817-63-3 |
| BAY11-7082 | MCE (Mori et al., 2002) | CAS 19542-67-7 |
| DUB-IN-1 | MCE (Colombo et al., 2010) | CAS 924296-18-4 |
| DUB-IN-2 | MCE (Colombo et al., 2010) | CAS 924296-19-5 |
| E-64 | Selleck (Wadhawan et al., 2014) | CAS 66701-25-5 |
| GRL0617 | MCE (Ratia et al., 2008) | CAS 1093070-16-6 |
| GW7647 | MCE (Luo et al., 2017) | CAS 265129-71-3 |
| HBX41108 | MCE | CAS 924296-39-9 |
| HY-13487 | MCE (Weinstock et al., 2012) | CAS 1247825-37-1 |

(Continued on next page)
Continued

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| HY-17541A           | MCE    | NA         |
| IU1                 | Selleck (Lee et al., 2010) | CAS 314245-33-5 |
| LDN57444            | MCE (Liu et al., 2003) | CAS 668467-91-2 |
| LY-3000328          | MCE (Jadhav et al., 2014) | CAS 1373215-15-6 |
| Mitoxantrone        | Selleck (Takeuchi et al., 1992) | CAS 70476-82-3 |
| ML323               | MCE (Liang et al., 2014) | CAS 1572414-83-5 |
| NSC632839           | MCE (Nicholson et al., 2008) | CAS 157654-67-6 |
| Odanacatib          | Selleck (Gauthier et al., 2008) | CAS 603139-19-1 |
| P20777              | MCE (Altun et al., 2011) | CAS 1247819-59-5 |
| Pimozide            | MCE (Ybema et al., 1994) | CAS 2062-78-4 |
| PYR-41              | Selleck (Yang et al., 2007) | CAS 418805-02-4 |
| SJ83-019A           | MCE (Mistry et al., 2013) | NA |
| Spautin-1           | Selleck (Shao et al., 2014) | CAS 1262888-28-7 |
| TCID                | Selleck (Liu et al., 2003) | CAS 30675-13-9 |
| WP1130              | Selleck (Barholomeusz et al., 2007) | CAS 856243-80-6 |
| 4E1Rcat             | Selleck (Cencic et al., 2011) | CAS 328998-25-0 |
| Avasimibe           | Selleck (Tardif et al., 2004) | CAS 166518-60-1 |
| CPI-169             | Selleck (Vidya Balasubramanian, 2014) | CAS 1450655-76-1 |
| GW4064              | Selleck (Akabi-Ameyaw et al., 2008) | CAS 278779-30-9 |
| RG-7388             | MCE (Ding et al., 2013) | CAS 1229705-06-9 |
| Tiplatinin          | Selleck (Hennan et al., 2008) | CAS 393105-53-8 |
| UMI-77              | Selleck (Abulwerdi et al., 2014) | CAS 518303-20-3 |
| Vitamin B12         | Selleck (Banerjee, 2003) | CAS 68-19-9 |
| Zafirlukast         | Selleck (Finnerty et al., 1992) | CAS 107753-78-6 |
| Zinc Pyrithi ne     | Selleck (Ermolayeva adn Sanders, 1995) | CAS 13463-41-7 |
| 8                   | ChemDiv | www.chemdiv.com |
| 9                   | ChemDiv | www.chemdiv.com |
| 10                  | ChemDiv | www.chemdiv.com |

Critical commercial assays

| Assay                              | Source         | Catalogue Number |
|------------------------------------|----------------|------------------|
| SPR analysis                       | GE Healthcare  | Cat# BR-1005-30  |
| NF-κB activity luciferase-reporting system | Transgene      | Cat# FR201-02    |
| CellTiter-Glo luminescent cell viability assays | Promega         | Cat# G7570       |
| Microsomal stability assay         | Corning® Gentest™ | Cat# 452701     |

Deposited data

| Structure                          | Source             | PDB ID      |
|------------------------------------|--------------------|-------------|
| SCoV2 Plpro apo structure          | This paper         | 7D6H        |
| SCoV2 Plpro/12 structure           | This paper         | 7E35        |
| SCoV2 Plpro/GRIL617 structure      | Osipiuk et al., 2021 | 7JIR        |
| SCoV2 Plpro/Ub structure           | Klemm et al., 2020 | 6XAA        |
| SCoV2 Plpro/ISG15 structure        | Shin et al., 2020  | 6YVA        |

Experimental models: cell lines

| Model                              | Source               | N/A   |
|------------------------------------|----------------------|-------|
| Human: 293T                        | Li Tan’s laboratory  | N/A   |
| Human: SCoV2 PlproWT A549          | This paper           | N/A   |
| Human: SCoV2 PlproC112S A549       | This paper           | N/A   |
| Human: hACE2-HeLa                  | Vitalstar            | N/A   |

Recombinant DNA

| Construct                          | Source              | N/A   |
|------------------------------------|---------------------|-------|
| pET32a-6xHis-3C-PlproWT            | This paper          | N/A   |
| pET32a-6xHis-3C-PlproC112S         | This paper          | N/A   |
| pET32a-6xHis-Ub2                   | This paper          | N/A   |

(Continued on next page)
RESOURCE AVAILABILITY

Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by Lead Contact Li Tan (tanli@sioc.ac.cn).

Material availability
Plasmid, Probe 2-7 and all compounds can be requested through contacting the Lead Contact.

Data and code availability
The accession numbers for the crystal structures reported in this paper are PDB: 7D6H and PDB: 7E35.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Cell lines and cell culture
HEK293T / SCoV2 PLpro^{WT} A549 / SCoV2 PLpro^{C112S} A549
HEK293T (human embryonic kidney cells; hypotriploid; female; fetal) were obtained from Junhao Hu’s laboratory and were not further authenticated. A549 expressing WT SCoV2 PLpro or C112S mutant SCoV2 PLpro were constructed in this paper. hACE2-Hela cells were purchased from Vitalstar. Cells were grown in Dulbecco’s Modified Eagle’s medium (DMEM, Gibco) supplemented with 10% (v/v) fetal bovine serum (FBS, Gibco), 50 units/mL penicillin, 50 units/mL streptomycin. Cells were incubated in 5% CO₂ at 37 °C. Cell lines were passaged every 72 hours with trypsin and not allowed to reach confluency.

293T cells / A549 lung adenocarcinoma cells
293T cells (female) and A549 lung adenocarcinoma cells (male) were obtained from ATCC. hACE2-HeLa cells (female) were obtained from Vitalstar. All the cells were cultured in Dulbecco Modified Eagle medium (DMEM) with 10% FBS and 100 U/mL penicillin-streptomycin at 37°C/5% CO₂ in a humidified environment.

METHOD DETAILS

Protein expression and purification
DNA fragment that encodes full-length PLpro of SCoV2 was synthesized and cloned into a modified pET32a vector which fuses a 6XHis tag and an HRV 3C protease cutting sequence to the N-terminal of PLpro. C112S point mutation was introduced by the standard PCR-based mutagenesis method and verified by Sanger sequencing.

PLpro wild-type and C112S mutant proteins were expressed in E. coli BL21(DE3). Specifically, when the OD₆₀₀ of bacteria culture reached about 0.8, zinc chloride was supplemented to the culture with a final concentration of 0.1 mM and protein expression was
induced with 0.1 mM IPTG at 16 °C for 18 hours. The bacterial cells were pelleted by centrifugation and resuspended in binding buffer (50 mM Tris–HCl at pH 7.9, 500 mM NaCl and 5 mM imidazole) and disrupted with a high-pressure homogenizer FB-110S (Shanghai Litu Machinery Equipment Engineering Co., Ltd.). Supernatant of the lysate after centrifugation at 16,000g for 30 min was subjected to His-tag affinity purification with Ni²⁺–NTA agarose (GE Healthcare). The N-terminal 6xHis tag was cut by homemade HRV 3C protease and removed by size-exclusion chromatography on an HiLoad Superdex 26/60 column (GE healthcare) equilibrated in a buffer containing 20 mM Tris–HCl at pH 7.5, 100 mM NaCl and 1 mM DTT.

The wild-type ubiquitin and its mutants (K48R, K63R or Ub-D77 which contains a glutamate following the last G76 residue of Ub) were expressed as 6xHis-tagged recombinant proteins in E. coli BL21(DE3) and purified in a similar manner as SCoV2 PLpro.

**Preparation of Di-Ubiquitin proteins**

K48- and K63-linked di-ubiquitin were synthesized according to published protocols (Hofmann and Pickart, 2001; Plotrowski et al., 1997). For M1-linked di-ubiquitin preparation, two tandem repeats of coding sequence for human ubiquitin were cloned into a modified pET32a vector which fuses a 6xHis tag and an HRV 3C protease cutting sequence to the N-terminal of insert. The M1-linked di-ubiquitin was expressed and purified in a similar way as mono-ubiquitin.

**Protein crystallization and structural determination**

Crystallization of apo-form SCoV-2 PLproC112S was set up in hanging-drop manner at 16 °C by mixing fresh protein (10 or 15 mg/mL in buffer containing 20 mM Tris–HCl at pH 7.5, 100 mM NaCl and 1 mM DTT) with equal volume of reservoir solution (0.1 M acetate buffer pH 4.5, 0.8 M NaH₂PO₄/1.2M K₂HPO₄) and incubated at 16 °C.

For the crystal growth of PLproC112S/compound complex, PLproC112S protein (10 mg/mL) was incubated with 3 mM compound 12 at 4 °C overnight and then used to set up crystallization in sitting-drops by mixing protein/compound with equal volume of reservoir solution which contains 0.1 M sodium citrate tribasic dihydride at pH 5.5 and 16% (v/v) PEG 8000.

After about 10 days, both apo-form and complex crystals appeared and were harvested in reservoir solution supplemented with 25% (v/v) glycerol as cryo-protectant and flash frozen in liquid nitrogen. Diffraction datasets were collected at the beamline BL17U1 of the Shanghai Synchrotron Radiation Facility (SSRF). The diffraction data sets were processed with XDS program and the autoPROC suite (Kabsch, 2010; Tickle et al., 2018; Vonrhein et al., 2011).

The initial phase for the structure of both apo-form and complex form were solved by molecular replacement using the PDB entry 6W9C as the search model with program Phaser (McCoy et al., 2007). The structural model was further manually re-built in Coot and refined with Phenix (Emsley et al., 2010; Liebschner et al., 2019). The qualities of final models were validated by MolProbity and listed in Table S2 (Williams et al., 2018). All the structural figures were prepared in program PyMol.

**Molecular docking study**

The docking study of 19 was performed based on coordinates of SCoV2 PLpro-12 (Chain A, PDB 7E35) and Schrödinger Glide software (Friesner et al., 2006). Meanwhile, 12 as a control was docked back with same parameters. GlideScores simulate binding free energies, more negative values represent tighter good binding, and scores of -10 or lower usually represent very good binding. In this study, the GlideScore for the top-ranking predicted binding mode of 19 was -11.814, in comparison, that for 12 was -10.851.

**Absorption and emission spectra**

Absorption and emission spectra were recorded by a Enspire Multimode plate reader (Perkin Elmer). Solutions of probes (20 μM, 20 mM Tris–HCl (pH 8.0), 100 mM NaCl, 5 mM 2-Hydroxy-1-ethanethiol) were added to the wells. The absorption was recorded between 300-600 nm, and then the Emission was recorded between 420-650 nm at an excitation of 405 nm.

**Kinetic assays**

Kinetic assay was performed in assay buffer (20 mM Tris–HCl, 100 mM NaCl, 5 mM 2-hydroxy-1-ethanethiol, pH 7.8) with 5 mM 2-hydroxy-1-ethanethiol as the reducing agent to eliminate cysteine-reactive compounds. 15 min was selected as the initial condition to compare these probes with different λ_ex and λ_em (probe 1: λ_ex = 485 nm; λ_em = 535nm; probe 2: λ_ex =345 nm; λ_em = 445nm; probe 3: λ_ex =330 nm; λ_em = 500nm; probe 5/6/7: λ_ex = 405 nm; λ_em = 450nm). PLproC112S was used to determine whether signal generation was dependent on enzyme activity. Enzyme concentration (PLpro 1 μM) and incubation time with substrate were optimized to yield a linear response in a 60-mintime frame (probe 5, 2.5μM), and a 30-mintime frame (probe 7, 2.5 μM) for HTS Screening. The enzyme activity was monitored using the Enspire Multimode Plate Reader (Perkin Elmer).

**K_M value determination**

The assay was performed in a 40 μL reaction volume using a black flat-bottom 384-well plates (Greiner Bio-One, #781076). We used the substrate after cleaving the quencher to make the standard curve of substrate concentration and signal value. Initial velocity of enzymatic reaction was plotted over time within the linear range in various concentrations of enzyme and substrates. According to the Michaelis equation, the initial velocity and substrate concentration were plotted to get the K_M value:

\[ V_0 = \frac{V_{max}[S]}{K_{M} + [S]} \]
Where $V_0$ is initial velocity of enzymatic reaction, $V_{\text{max}}$ is the reaction rate when the enzyme is saturated with the substrate, $|S|$ is substrate concentration, and $K_M$ is Michaelis constant.

**HTS screening**

A compound library consisting of 35,360 structurally diverse small molecules was purchased from Chemdiv and maintained as 5 mg/ml stock solutions dissolved in DMSO and stored at -20°C. The automated liquid dispensing of primary screen was performed on Echo 550 (Labcyte) and Viafill (Integra). Fluorescence values were measured on Enspire Multimode Plate Reader (PerkinElmer). All assays were performed in duplicate at room temperature, using black flat-bottom 384-well plates (Greiner Bio-One, #784076) containing a final reaction volume of 20 μL. The assays were assembled as follows: 20 nL compounds (final concentration 5 μg/ml) was dispensed into wells and then incubated with 10 μL of 2 μM PLpro (final concentration 1 μM) in Buffer A (20 mM Tris-HCl, 100 mM NaCl, 5 mM 2-hydroxy-1-ethanethiol, pH 7.8) for 30 min. Reactions were initiated with 10 μL of 5 μM probe 5 (final concentration 2.5 μM) in Buffer A, shaken vigorously for 10 sec, and then incubated for 60 min, before measuring fluorescence emission intensity ($λ_{\text{ex}} = 405$ nm; $λ_{\text{em}} = 450$ nm). Each 384-well plate contained 11 positive control wells (20 nL of DMSO replacing 20 nL of inhibitor in DMSO), 12 negative control wells (assay components lacking PLpro) and 1 positive inhibitor control well (20 nL of 10 mM GRL0617). Compounds that showed Z-scores of less than -8 were cherry picked for further analysis.

**IC$_{50}$ value determination**

IC$_{50}$ values for all inhibitors were determined in 384-well format. The final enzyme concentrations were 1 μM and 0.5 μM for probe 7 and Ub-Rho, respectively, and the final substrate concentrations were 2.5 μM and 0.5 μM in a 30 min time frame and a 5 min time frame. The assays were performed at room temperature, and the enzyme activity was monitored as described above.

**SPR analysis**

SPR experiment was performed by Biacore T200 (GE Healthcare) at 20°C. PBS-P buffer was filtered through a 0.22 μm membrane filter and degassed prior to use. First, PLpro protein was immobilized on the CM5 chip surface. PLpro protein was diluted to 50 μg/mL using sodium acetate flowing at pH 5.5. The diluted protein flowed at 10 μL/min and was soon covalently immobilized to a flow cell of CM5 sensor chip via primary amine group, using standard Amine Coupling Kit. The final level of immobilized protein was 13537 RU. A flow cell without coupling proteins was used as a blank reference. Small molecules were diluted in PBS-P buffer in a series of concentrations (1.25-125 μM for GRL0617, 0.24-125 μM for 19) and flowed over the immobilized PLpro or blank cell at 30 μL/min with 90 s contact time and 120 s dissociation time. The equilibrium dissociation constant ($K_d$) was used to evaluate the binding activity of each compound. Considering the influence of non-specific binding, we used non-specific binding function to fit the curve in GraphPad Prism. Then subtract the non-specific contribution from the original data, and we got the actual specific binding response. $K_d$ was then calculated this response ($R$) and the corresponding concentration ($|S|$) with the formula below.

$$R = \frac{V_{\text{max}}|S|}{|S| + K_M}$$

**Inhibitor specificity assay**

To verify the specificity of inhibitor, Ub-Rho was used as substrate of PLpro and the release of Rhodamine 110 was measured by fluorescence intensity (Ex./Em. 485/535 nm) on 384-well microplate reader (Enspire, PerkinElmer). Compound 19 (10 μM) was incubated with 10 μL different DUBs (suitable concentration) for 1 h at RT respectively and reaction was initiated by addition of 10 μL Ub-Rho (1 μM) to the well. The reaction was maintained at 37°C until the appropriate fluorescence intensity value was reached. The experiment was repeated three times.

**Nsp1-Nsp2 cleavage assay**

4 x 10$^5$ HEK293T cells per well were seeded onto 12-well plates a day before pretreated with compounds for 1 h, and then transiently transfected with 500 ng nsp1-nsp2-flag and 250 ng w/o Flag-SCoV2-PLpro plasmid. 24h after transfection, cell lysates were collected and analyzed for nsp1-nsp2-cleavage by immunoblot analysis.

**NF-κB activity luciferase-reporting assay**

1x10$^5$ HEK293T cells per well were seeded onto 96-well plates and transiently transfected with 0.02 μg p65 reporter construct bearing firefly luciferase, 0.01 μg construct bearing renilla luciferase downstream of CMV promoter and w/o Flag-SCoV2-PLpro plasmid. 18 h after seeding, HEK293T cells were stimulated with TNF-α (200 ng/mL) for 6 h and then firefly and renilla luciferase activity was determined with TransDetect double-luciferase reporter assay kit (Transgene, FR201-02) according to the manufacturers' instruction.

**DelsISGylation assay**

A549 cells stably expressing of PLproWT or PLproC112S mutant were pretreated with compounds (10 μM) for 6 h, and treated with 1.25 nM IFN-α for 24 h to induce ISGylation. Cells were lysed with lysis buffer (100 mM Tris-HCl (pH 8.0), 1% (w/v) SDS), boiled at 95°C for 10 min and protein concentration was measured with BCA assay (Thermo Fischer). 10 μg cell lysates were loaded onto
13.5% Tris-Glycin PAGE gel, transferred to nitrocellulose using a semi-dry transfer apparatus (0.2 A for 90 mins), and blocked for 30 mins at RT. The membrane was incubated with anti-ISG15 (1:1000 in 3% BSA, Invitrogen #703131) at 4 °C overnight and incubated with secondary antibody (1:5000) for 1 h at RT.

**SARS-CoV2 infection and evaluation of antiviral activities**
A clinically isolated SARS-CoV2 (SZ02) was propagated in Vero-E6 cells, viral titer was determined by 50% tissue culture infective dose (TCID₅₀). All the infection experiments were performed in a biosafety level-3 (BLS-3) laboratory. To evaluate the antiviral efficacy of these inhibitors, hACE2-Hela cells were cultured in 24-well plate (1 x 10⁵ cells/well) or in 96-well plate (1 x 10⁴ cells/well) overnight, and then infected with 0.3 MOI virus for 2 h. The supernatant was removed and the cells were washed 3 times with PBS, then cultured with fresh medium plus inhibitors at indicated doses. At 48 h post infection, cells were collected with 2X SDS sample buffer for immunoblotting with antibody against SCoV2 NP (Sino Biological 40143-R019), or fixed with 4% PFA and immunostained with anti-Spike antibody (Sinobiologica, 40150-T62). The nuclei were stained with DAPI (Beyotime, China). The images were recorded with fluorescence microscopy.

To evaluate the cytotoxicity of the inhibitors, 2 x 10⁴ cells/well hACE2-HeLa cells cultured in 384-well plate were treated with each inhibitor at indicated concentrations for 72 h, then subjected to viability assays (CellTiter-Glo, Promega) followed with measuring and quantification.

**Metabolic stability studies**
Inhibitor 19 or Verapamil (control) and mouse liver microsomes (MLM) were primarily incubated in a thermostat water bath maintained at 37 °C for 5 min (250 μL containing 1.5 μM compound and 750 ng/mL MLM in PBS). The primary incubations were divided into 7 tubes with 30 μL which was added into 15 μL NADPH (3 mM) or 15 μL PBS, and incubated in a thermostat water bath maintained at 37 °C. At various time points, e.g., 0, 5, 10, 20, 30, 60 min (all above with 15 μL NADPH), 60 min (with 15 μL PBS), incubations were quenched with 90 μL ice-cold acetonitrile containing 100 ng/mL IS. These mixtures were centrifuged at 15,000 rpm for 1 min, the liquid supernatants were transferred to clean tubes. After diluted with water (1:1), the incubations were analyzed by LC-MS.

Inhibitor 19 (0.25 mM in PBS) and mouse plasma were incubated in a thermostat water bath maintained at 37 °C (200 μL, containing 8.35 μM compound). At various time points, e.g., 0, 15, 30, 60, 120 min, 30 μL incubations were quenched with 120 μL ice-cold acetonitrile containing 100 ng/mL IS. These mixtures were centrifuged at 10,000 rpm for 10 min, the liquid supernatants were transferred to clean tubes. After diluted with water (1:1), the incubations were analyzed by LC-MS.

**Chemical synthesis**

**General synthetic procedures**
Unless otherwise noted, reagents and solvents were obtained from commercial suppliers and were used without further purification. Reactions were run in round-bottom flasks or glass vials and stirred with Teflon-coated magnetic stir bars. Solvent evaporation was performed on rotary evaporator (Buchi) under reduced pressure. Reactions were monitored by thin layer chromatography or LC-MS (Waters). Acquity H-Class UPLC/MS with QDa mass spectrometer using water + 0.05% formic acid (solvent A) and acetonitrile + 0.05% formic acid (solvent B). Preparative HPLC was performed on a Waters Sunfire C18 column (19 x 100 mm, 5μM) using a gradient of 10-95% acetonitrile in water containing 0.05% trifluoroacetic acid (TFA) over 10 min (15 min run time) at a flow rate of 15 mL/min. ¹H/¹³C NMR spectra were recorded at ambient temperature on Bruker DMAX 400 (400 MHz for ¹H NMR and 101 MHz for ¹³C NMR) instruments in the specified deuterated solvents. Observed proton absorptions were reported as δ units of parts per million (ppm) relative to tetramethylsilane (δ 0.0). Multiplicities were reported: s (singlet), d (doublet), t (triplet), q (quartet), dd (doublet of doublets) and m (multiplet). Coupling constants were reported as a J value in Hertz (Hz).

Abbreviations used in this section: THF = tetrahydrofuran; DCM = dichloromethane; DMF = N,N-dimethylformamide; DMSO = dimethyl sulfoxide; DCE = 1,2-dichloroethane; DIPEA = diisopropylethylamine; EA = ethyl acetate; TFA = trifluoroacetic acid; HCl = hydrochloric acid; RT = room temperature.

**Reaction schemes**

---

Cell Chemical Biology 28, 855–865.e1–e9, June 17, 2021 e6
Reagents and conditions: (a) Ms₂O, DIEA, DCM, 40 min, 0 °C; (b) ethyl isonipecotate, DCM, RT, 16 h; (c) 1 M NaOH, MeOH, RT, 16 h; (d) EDCI, HOBt, DIEA, DCM, RT, 16 h.

**Ethyl (R)-1-(1-(naphthalen-1-yl) ethyl) piperidine-4-carboxylate (21)**. (S)-1-(naphthalen-1-yl) ethan-1-ol (500 mg, 2.9 mmol) was dissolved in dry DCM (14.5 mL) at 0 °C. With continuous stirring at 0 °C, DIEA (2 mL, 11.6 mmol) was added, and Ms₂O (758 mg, 4.35 mmol) was added dropwise. The solution was stirred for 40 min at 0 °C, at which point ethyl piperidine-4-carboxylate (0.32 mL, 2.03 mmol) was added. The mixture was then stirred for 16 h at room temperature. The reaction mixture was quenched with water and extracted with CH₂Cl₂, washed with 10% aqueous Na₂CO₃. The organic layer was then dried (Na₂SO₄), filtered, and removed in vacuo. The residue was purified by silica gel column chromatography to furnish compound 21 in 54% yield (slightly yellow oil). ¹H NMR (400 MHz, DMSO-d₆) δ 8.46 – 8.40 (m, 1H), 7.93 – 7.88 (m, 1H), 7.79 (dd, J = 8.1, 1.3 Hz, 1H), 7.54 – 7.44 (m, 4H), 4.15 (q, J = 6.7 Hz, 1H), 4.06 – 4.01 (m, 2H), 2.96 (d, J = 11.3 Hz, 1H), 2.76 – 2.68 (m, 1H), 2.08 (tdd, J = 11.2, 8.0, 4.0 Hz, 1H), 1.84 – 1.77 (m, 1H), 1.74 – 1.67 (m, 1H), 1.55 – 1.45 (m, 2H), 1.39 (d, J = 6.7 Hz, 3H), 1.15 (t, J = 7.1 Hz, 3H).

**Ethyl (R)-1-(1-(naphthalen-1-yl) ethyl) piperidine-4-carboxylic acid (22)**. 21 (300 mg, 0.96 mmol) was dissolved in methanol (15 mL), followed by the addition of 1 N sodium hydroxide (2 mL, 2 mmol) in one portion. The resulting mixture was stirred for 16 h at room temperature, then concentrated in vacuo, and dissolved in small amount of water. The solution was treated with AcOH dropwise until the solution was acidic by pH paper. The residue was purified by reversed phase column chromatography to furnish compound 22 in 98% yield (white solid). ¹H NMR (400 MHz, DMSO-d₆) δ 8.38 (d, J = 8.5 Hz, 1H), 8.07 – 8.03 (m, 2H), 7.88 (dt, J = 7.4, 2.1 Hz, 1H), 7.73 – 7.57 (m, 4H), 5.46 – 5.38 (m, 1H), 3.90 (d, J = 12.2 Hz, 2H), 3.10 (s, 1H), 2.39 (s, 6H), 1.94 (d, J = 14.1 Hz, 1H), 1.83 (d, J = 13.0 Hz, 1H), 1.75 (d, J = 6.7 Hz, 3H), 1.64 (d, J = 11.7 Hz, 1H).

**N-(3-(aminomethyl)-5-fluorophenyl) acetamide (14c)**. 3-amino-5-fluorobenzonitrile (500 mg, 4 mmol) was dissolved in THF (3 mL), followed by the addition of acetic anhydride (0.58 mL, 6 mmol) in one portion. The residue was purified by reversed phase column chromatography to furnish compound 14c in 92% yield (white solid). ¹H NMR (400 MHz, DMSO-d₆) δ 10.46 (s, 1H), 7.80 – 7.76 (m, 2H), 7.50 (dd, J = 8.4, 2.4, 1.4 Hz, 1H), 2.09 (s, 3H). To a solution of 14a (300 mg, 1.68 mmol) in saturated ammonia in MeOH, Raney-Ni (30 mg, 10%) was added, and the mixture was stirred under H₂ atmosphere at room temperature for 16 h. The reaction was filtered through a celite pad and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to furnish compound 14c in 98% yield (slightly yellow oil).

**N-(3-(aminomethyl) phenyl)-2-(dimethylamino) acetamide (16c)**. To a solution of dimethylglycine (600 mg, 5.82 mmol), EDCI (1.12 g, 5.82 mmol), and HOBt (0.79 g, 5.82 mmol) in dry DCM (20 mL) were added a solution of DIEA (4.2 mL, 24.2 mmol) and 3-aminobenzonitrile (573 mg, 4.85 mmol) in dry CH₂Cl₂ (20 mL) at 0 °C under argon atmosphere, and it was allowed to stir for 16 h at room temperature. The reaction mixture was quenched with water and extracted with CH₂Cl₂. The organic layers were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to furnish compound 16c in 36% yield (slightly yellow oil). ¹H NMR (400 MHz, DMSO-d₆) δ 9.31 (s, 1H), 8.03 – 7.97 (m, 1H), 7.81 (ddd, J = 8.0, 2.2, 1.4 Hz, 1H), 7.48 – 7.41 (m, 1H), 7.38 (dt, J = 7.7, 1.4 Hz, 1H), 3.10 (s, 2H), 2.39 (s, 6H).
To a solution of 16a (200 mg, 0.98 mmol) in saturated ammonia in MeOH, Raney-Ni (20 mg, 10%) was added, and the mixture was stirred under H₂ atmosphere at room temperature for 16 h. The reaction was filtered through a celite pad and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to furnish compound 16c in 98% yield (slightly yellow oil).

N-(3-aminomethyl)phenyl)-4-methylpiperazine-1-carboxamide (17c). A solution of 3-isocyanatobenzonitrile (100 mg, 0.69 mmol) and 1-methylpiperazine (76 mg, 0.76 mmol) in diethyl ether (1.7 ml) prepared at room temperature, and was stirred at the same temperature. The reaction was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to furnish compound 17b in 83% yield (colorless oil). ¹H NMR (400 MHz, DMSO-d₆) δ 8.28 (s, 1H), 7.93 (t, J = 1.9 Hz, 1H), 7.74 (dd, J = 8.4, 2.3, 1.2 Hz, 1H), 7.44 (t, J = 7.9 Hz, 1H), 7.37 (dt, J = 7.6, 1.4 Hz, 1H), 3.45 (t, J = 5.0 Hz, 4H), 2.32 (t, J = 5.0 Hz, 4H), 2.20 (s, 3H).

To a solution of 17b (140 mg, 0.57 mmol) in saturated ammonia in MeOH, Raney-Ni (14 mg, 10%) was added, and the mixture was stirred under H₂ atmosphere at room temperature for 16 h. The reaction was filtered through a celite pad and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to furnish compound 17c in 98% yield (slightly yellow oil).

N-(3-aminomethyl)-5-fluorophenyl)-4-methylpiperazine-1-carboxamide (18c). To a solution of dimethylglycine (500 mg, 3.67 mmol), and HATU (1.67 g, 4.4 mmol) in dry DCM (20 ml) were added a solution of DIEA (3.2 mL, 18.3 mmol) and 3-amine-5-fluorobenzonitrile (454 mg, 4.4 mmol) in dry CH₂Cl₂ (17 ml) at 0°C under argon atmosphere, and it was allowed to stir for 16 h at room temperature. The reaction mixture was quenched with water and extracted with CH₂Cl₂. The organic layers were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to furnish compound 18a in 37% yield (white solid).

N-(3-aminomethyl)-5-fluorophenyl)-4-methylpiperazine-1-carboxamide (19c). 3-amine-5-fluorobenzonitrile (500 mg, 3.67 mmol) was dissolved in CH₂Cl₂ (10 ml), and added dropwise in portions to a solution of triphosgene (546 mg, 1.84 mmol) in CH₂Cl₂ (8.3 ml), and the mixture was stirred at the same temperature for 16 h. The reaction was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to furnish compound 19a in 52% yield (slightly yellow solid).

General Amide Coupling Method. To a solution of (R)-1-{(1-naphthalen-1-yl)ethyl} piperidine-4-carboxylic acid (0.05 g, 0.18 mmol), EDCI (0.04 g, 0.21 mmol), and HOBr (0.03 g, 0.21 mmol) in dry DCM (20 ml) were added a solution of DIEA (0.154 mL, 0.88 mmol) and amine (0.21 mmol) in dry CH₂Cl₂ (17 ml) at 0°C under argon atmosphere, and it was allowed to stir for 16 h at room temperature. The reaction mixture was quenched with water and extracted with CH₂Cl₂. The organic layers were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to furnish compound 19c in 98% yield (slightly yellow oil).

(R)-N-(3-fluorobenzyl)-1-{(1-naphthalen-1-yl)ethyl} piperidine-4-carboxamide (11). The title compound was obtained as described in the general procedure in 52% yield (white solid). ¹H NMR (400 MHz, DMSO-d₆) δ 8.46 (d, J = 8.2 Hz, 1H), 8.21 (t, J = 6.0 Hz, 1H), 7.91 (dd, J = 7.2, 2.4 Hz, 1H), 7.80 (d, J = 8.1 Hz, 1H), 7.55 – 7.43 (m, 4H), 7.33 (td, J = 7.9, 6.1 Hz, 1H), 7.07 – 6.96 (m, 3H), 4.24 (d, J = 6.0 Hz, 2H), 4.15 (q, J = 6.5 Hz, 1H), 3.07 (d, J = 11.2 Hz, 1H), 2.79 (d, J = 11.4 Hz, 1H), 2.18 – 2.12 (m, 1H), 2.05 – 1.97 (m, 2H), 1.72 (d, J = 12.7 Hz, 1H), 1.63 – 1.52 (m, 3H), 1.40 (d, J = 6.8 Hz, 3H).

(R)-N-(3-acetamidobenzyl)-1-{(1-naphthalen-1-yl)ethyl} piperidine-4-carboxamide (12). The title compound was obtained as described in the general procedure in 53% yield (white solid). ¹H NMR (400 MHz, DMSO-d₆) δ 8.46 (d, J = 8.2 Hz, 1H), 8.21 (t, J = 6.0 Hz, 1H), 8.24 (t, J = 5.9 Hz, 1H), 7.94 – 7.88 (m, 1H), 7.80 (d, J = 8.1 Hz, 1H), 7.56 – 7.40 (m, 6H), 7.19 (t, J = 7.8 Hz, 1H), 6.86 (d, J = 7.6 Hz, 1H), 4.19 (d, J = 5.9 Hz, 2H), 4.14 (d, J = 6.7 Hz, 1H), 3.07 (d, J = 10.9 Hz, 1H), 2.79 (d, J = 11.3 Hz, 1H), 2.13 (d, J = 6.6 Hz, 1H), 2.01 (s, 5H), 1.73 (d, J = 12.7 Hz, 1H), 1.57 (d, J = 12.2 Hz, 3H), 1.40 (d, J = 6.6 Hz, 3H).

(R)-N-(2-methoxyphyrin-4-yl) methyl)-1-{(1-naphthalen-1-yl)ethyl} piperidine-4-carboxamide (13). The title compound was obtained as described in the general procedure in 66% yield (white solid). ¹H NMR (400 MHz, DMSO-d₆) δ 8.46 (d, J = 8.1 Hz, 1H), 8.32 (t, J = 6.0 Hz, 1H), 8.05 (d, J = 5.2 Hz, 1H), 7.91 (dd, J = 7.9, 1.8 Hz, 1H), 7.80 (d, J = 8.1 Hz, 1H), 7.56 – 7.44 (m, 4H), 6.80 (dd, J = 5.3, 1.4 Hz, 1H), 6.59 – 6.56 (m, 1H), 4.20 (d, J = 6.0 Hz, 2H), 4.15 (q, J = 6.6 Hz, 1H), 3.81 (s, 3H), 3.07 (d, J = 11.2 Hz, 1H), 2.79 (d, J = 11.4 Hz, 1H), 2.17 (ddd, J = 11.6, 7.5, 4.1 Hz, 1H), 2.02 (ddd, J = 8.5, 5.6, 2.9 Hz, 2H), 1.73 (d, J = 12.9 Hz, 1H), 1.63 – 1.50 (m, 3H), 1.40 (d, J = 6.6 Hz, 3H).

(R)-N-(3-acetamido-5-fluorobenzyl)-1-{(1-naphthalen-1-yl)ethyl} piperidine-4-carboxamide (14). The title compound was obtained as described in the general procedure in 41% yield (white solid). ¹H NMR (400 MHz, DMSO-d₆) δ 10.09 (s, 1H), 8.46 (d, J = 8.1 Hz, 1H),
11.6 Hz, 2H), 1.65 (d, J = 8.1 Hz, 1H), 8.28 (t, J = 8.1 Hz, 1H), 3.08 (d, J = 10.9 Hz, 1H), 2.80 (d, J = 11.2 Hz, 1H), 2.13 (d, J = 9.2 Hz, 1H), 2.02 (d, J = 1.1 Hz, 5H), 1.74 (d, J = 13.0 Hz, 1H), 1.58 (m, 3H), 1.40 (d, J = 6.5 Hz, 3H).

(R)-N-(3-(2-(dimethylamino) acetamido)-5-fluorobenzyl)-1-(1-(naphthalen-1-yl) ethyl) piperidine-4-carboxamide (18). The title compound was obtained as described in the general procedure in 55% yield (white solid). 1H NMR (400 MHz, DMSO-d6) δ 8.45 (d, J = 8.0 Hz, 1H), 7.11 (dd, J = 7.9, 1.7 Hz, 1H), 7.91 (d, J = 6.0 Hz, 1H), 6.89 (dt, J = 7.7, 1.4 Hz, 1H), 4.19 (d, J = 5.9 Hz, 2H), 4.15 (s, 1H), 3.09 (s, 3H), 2.79 (d, J = 11.1 Hz, 1H), 2.28 (s, 6H), 2.15 (s, 1H), 2.01 (s, 2H), 1.73 (d, J = 12.5 Hz, 1H), 1.58 (d, J = 13.0 Hz, 3H), 1.41 (d, J = 6.6 Hz, 3H).

(R)-N-((1-methylpiperidin-4-yl) methyl)-1-(1-(naphthalen-1-yl) ethyl) piperidine-4-carboxamide (15). The title compound was obtained as described in the general procedure in 43% yield (white solid). 1H NMR (400 MHz, DMSO-d6) δ 8.06 (d, J = 8.0 Hz, 2H), 8.20 (t, J = 6.0 Hz, 1H), 7.91 (dd, J = 7.9, 1.7 Hz, 1H), 7.80 (d, J = 8.1 Hz, 1H), 7.56 – 7.44 (m, 4H), 7.29 (dt, J = 7.1, 1.8 Hz, 2H), 7.16 – 7.10 (m, 1H), 6.77 (dt, J = 7.5, 1.4 Hz, 1H), 4.17 (d, J = 5.9 Hz, 2H), 4.14 (d, J = 6.5 Hz, 1H), 3.40 (d, J = 10.1 Hz, 3H), 3.07 (d, J = 10.9 Hz, 1H), 2.78 (d, J = 11.2 Hz, 1H), 2.28 (t, J = 5.0 Hz, 4H), 2.18 (s, 3H), 2.09 (s, 3H), 1.99 (dd, J = 10.6, 6.7 Hz, 2H), 1.72 (d, J = 12.8 Hz, 1H), 1.57 (d, J = 11.3 Hz, 2H), 1.40 (d, J = 6.6 Hz, 3H).

(R)-N-(3-(2-(dimethylamino) acetamido)-5-fluorobenzyl)-1-(1-(naphthalen-1-yl) ethyl) piperidine-4-carboxamide (18). The title compound was obtained as described in the general procedure in 55% yield (white solid). 1H NMR (400 MHz, DMSO-d6) δ 8.86 (d, J = 6.0 Hz, 1H), 8.28 (t, J = 6.0 Hz, 1H), 7.91 (dd, J = 7.9, 1.7 Hz, 1H), 7.80 (d, J = 8.1 Hz, 1H), 7.56 – 7.44 (m, 5H), 7.30 (d, J = 1.7 Hz, 1H), 6.69 (dd, J = 9.5, 2.2 Hz, 1H), 4.19 (d, J = 6.0 Hz, 2H), 4.15 (d, J = 6.7 Hz, 1H), 3.05 (s, 3H), 2.79 (d, J = 11.3 Hz, 1H), 2.24 (s, 6H), 2.18 – 2.12 (m, 1H), 2.06 – 1.98 (m, 2H), 1.73 (d, J = 12.6 Hz, 1H), 1.63 – 1.52 (m, 3H), 1.40 (d, J = 6.6 Hz, 3H).

(R)-N-(3-fluoro-5-((1-(1-(naphthalen-1-yl) ethyl) piperidine-4-carboxamido) methyl) phenyl) piperazine-1-carboxamide (17). The title compound was obtained as described in the general procedure in 45% yield (white solid). 1H NMR (400 MHz, DMSO-d6) δ 8.68 (s, 1H), 8.48 – 8.44 (m, 1H), 8.25 (t, J = 6.0 Hz, 1H), 7.93 – 7.89 (m, 1H), 7.80 (d, J = 8.1 Hz, 1H), 7.55 – 7.45 (m, 4H), 7.28 (dt, J = 11.9, 2.3 Hz, 1H), 7.11 (t, J = 1.7 Hz, 1H), 6.56 (ddd, J = 9.5, 2.5, 1.4 Hz, 1H), 4.16 (d, J = 6.0 Hz, 2H), 4.14 (s, 1H), 3.41 (t, J = 5.0 Hz, 4H), 3.07 (d, J = 11.2 Hz, 1H), 2.79 (d, J = 11.1 Hz, 1H), 2.29 (t, J = 5.0 Hz, 4H), 2.19 (s, 3H), 2.15 (d, J = 5.9 Hz, 1H), 2.01 (s, 2H), 1.73 (d, J = 12.9 Hz, 1H), 1.55 (m, 3H), 1.40 (d, J = 6.6 Hz, 3H).

QUANTIFICATION AND STATISTICAL ANALYSIS

All statistical analyses and curves were produced using GraphPad Prism 8. All the enzymatic activity assay were performed in triplicate and quantified data were presented as mean ± SD.

For microscopy experiments, fluorescence intensities were quantified with ImageJ software. Data was presented as mean ± SD of three experimental replicates.

IC50 values were calculated by means of non-linear regression using Graphpad Prism 8 and were shown as data points representing as mean ± SD.